
The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Supplements and Featured Publications
about 23 years ago
Antithrombotic Therapy for the Treatment of Venous Thromboembolismabout 23 years ago
Participating Faculty





